ASCO 2016

A Novel, Targeted Drug Yields Promising Results In Stomach And Esophageal Cancer
Forbes
Mon, 06/20/16 - 10:18 am
ASCO 2016
Claudiximab
antibodies
Ganymed
stomach cancer
esophageal cancer
AbbVie's Rova-T Update at ASCO: Good or Bad?
Motley Fool
Sun, 06/12/16 - 09:54 pm
AbbVie
Rova-T
ASCO 2016
small cell lung cancer
Immunomedics' ASCO Letdown
Motley Fool
Sat, 06/11/16 - 09:57 am
ASCO 2016
Immunomedics
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
Fri, 06/10/16 - 04:16 pm
biotech
ASCO 2016
Biogen
Immunomedics
AbbVie
Juno Therapeutics
Kite Pharma
U.S. regulator says too many drugmakers chasing same cancer strategy
Yahoo/Reuters
Fri, 06/10/16 - 08:53 am
FDA
oncology
ASCO 2016
Merck
Bristol-Myers Squibb
PD-1 inhibitors
Exelixis, Inc. Gets Some ASCO Love
Motley Fool
Tue, 06/7/16 - 11:16 am
Exelixis
ASCO 2016
Cabometyx
renal cell carcinoma
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Seeking Alpha
Tue, 06/7/16 - 11:12 am
JNJ
Multiple Myeloma
daratumumab
ASCO 2016
Biotech Stocks: Much Ado About Nothing at ASCO?
Barron's
Mon, 06/6/16 - 11:30 pm
ASCO 2016
biotech
Celgene
Amgen
Regeneron
Gilead Sciences
Juno Therapeutics leaps on promising clinical data
CNBC
Mon, 06/6/16 - 11:07 pm
Juno Therapeutics
clinical trials
CAR-T
JCAR014
acute lymphoblastic leukemia
ASCO 2016
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Yahoo
Mon, 06/6/16 - 11:23 am
AbbVie
Imbruvica
CLL
small lymphocytic lymphoma
ASCO 2016
Why ProNAi Could Be the Biggest Loser at ASCO
24/7 Wall St
Mon, 06/6/16 - 11:20 am
ProNai
ASCO 2016
PNT2258
B-cell lymphoma
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
Yahoo
Mon, 06/6/16 - 11:04 am
Clovis Oncology
rucaparib
ovarian cancer
pancreatic cancer
ASCO 2016
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
Yahoo
Mon, 06/6/16 - 10:31 am
Lynparza
olaparib
ovarian cancer
AstraZeneca
ASCO 2016
Breast cancer study shows benefit to extended treatment with aromatase inhibitors
Stat
Sun, 06/5/16 - 12:09 pm
breast cancer
ASCO 2016
aromatase inhibitors
Novartis
Femara
Pfizer
Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug
Fierce Biotech
Sun, 06/5/16 - 12:05 pm
Ganymed
ASCO 2016
IMAB362
gastric cancer
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Yahoo
Sun, 06/5/16 - 12:03 pm
AbbVie
glioblastoma
brain cancer
ASCO 2016
ABT-414
J&J myeloma drug, in combo regimen, delays worsening of the disease
Yahoo/Reuters
Sun, 06/5/16 - 12:01 pm
JNJ
Multiple Myeloma
Darzalex
Takeda
Velcade
ASCO 2016
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Sun, 06/5/16 - 11:59 am
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Yahoo
Sun, 06/5/16 - 11:57 am
Keytruda
Merck
ASCO 2016
melanoma
New Roche med Tecentriq shines in study of untreated bladder cancer patients
Fierce Pharma
Sun, 06/5/16 - 11:52 am
Roche
Tecentriq
bladder cancer
ASCO 2016

Pages